Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production (Q39084413)

8 September 2017

title

Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production (English)

1 reference

8 September 2017

20

Ann M Bode

1 reference

8 September 2017

21

Zigang Dong

1 reference

8 September 2017

5

Haidan Liu

1 reference

8 September 2017

3

Qipan Deng

1 reference

8 September 2017

9

Xiangjian Luo

1 reference

8 September 2017

22

Jikai Liu

1 reference

8 September 2017

12

Xinxian Weng

1 reference

8 September 2017

23

Ya Cao

1 reference

8 September 2017

Xinfang Yu

1

1 reference

8 September 2017

Wei Li

2

1 reference

8 September 2017

Shuo You

4

1 reference

8 September 2017

Songling Peng

6

1 reference

8 September 2017

Xiaolan Liu

7

1 reference

8 September 2017

Jingchen Lu

8

1 reference

8 September 2017

Lifang Yang

10

1 reference

8 September 2017

Min Tang

11

1 reference

8 September 2017

Wei Yi

13

1 reference

8 September 2017

Wenbin Liu

14

1 reference

8 September 2017

Shengqi Wu

15

1 reference

8 September 2017

Zhihui Ding

16

1 reference

8 September 2017

Tao Feng

17

1 reference

8 September 2017

Jian Zhou

18

1 reference

8 September 2017

Jia Fan

19

1 reference

8 September 2017

publication date

20 December 2016

1 reference

8 September 2017

published in

Molecular Carcinogenesis

1 reference

8 September 2017

volume

56

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

1414-1426

1 reference

The angiogenic switch in carcinogenesis

8 September 2017

cites work

1 reference

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

21 January 2018

1 reference

A review of the current research on the role of bFGF and VEGF in angiogenesis

21 January 2018

1 reference

VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.

21 January 2018

1 reference

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

21 January 2018

1 reference

Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray

21 January 2018

1 reference

Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis

21 January 2018

1 reference

Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling.

21 January 2018

1 reference

Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways

21 January 2018

1 reference

Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway.

21 January 2018

1 reference

EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.

21 January 2018

1 reference

Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

21 January 2018

1 reference

Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor

21 January 2018

1 reference

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

21 January 2018

1 reference

EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinoma

21 January 2018

1 reference

Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis

21 January 2018

1 reference

EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms

21 January 2018

1 reference

ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases

21 January 2018

1 reference

Breast cancer statistics, 2013.

21 January 2018

1 reference

Forty-year journey of angiogenesis translational research

21 January 2018

1 reference

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

21 January 2018

1 reference

Evolution of bevacizumab-based therapy in the management of breast cancer

21 January 2018

1 reference

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

Neoalbaconol induces energy depletion and multiple cell death in cancer cells by targeting PDK1-PI3-K/Akt signaling pathway

21 January 2018

1 reference

The sponge/Matrigel angiogenesis assay.

21 January 2018

1 reference

ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner

21 January 2018

1 reference

The biology of VEGF and its receptors

21 January 2018

1 reference

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.

21 January 2018

1 reference

Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

21 January 2018

1 reference

Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1

21 January 2018

1 reference

EGFR antagonists in cancer treatment

21 January 2018

1 reference

Broad targeting of angiogenesis for cancer prevention and therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MC.22602

1 reference

8 September 2017

1 reference